pharmaphorum March 14, 2025
Phil Taylor

Antibody-drug conjugate (ADC) specialist Sutro Biopharma has shelved its lead drug for ovarian cancer and turned its attention to a trio of “next-generation” drugs still in preclinical development.

The dramatic decision – which has been accompanied by the laying off of around half its workforce and a change in chief executive – comes after Sutro revealed positive results from a phase 2/3 trial of lead drug luveltamab tazevibulin (luvelta, also known as STRO-002) in platinum-resistant ovarian cancer in December.

Sutro said at the time that the 32% objective response rate (ORR) in the dose-finding stage of the REFRαME-O1 study had set up the second pivotal stage of the trial, and it was hoping to file for accelerated approval of the...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma, Pharma / Biotech
FDA issues flu vaccine recommendations: 5 respiratory updates
CZI’s Priscilla Chan on ‘Virtual Cells’ AI Models to Cure Diseases
HIMSSCast: The 'genetic revolution' is underway
Walgreens PE Buyout Heavily Reliant on 83% Debt, Raising Concerns About Financial Stability
Common Trends in GLP-1 Use Amid Increased Indications

Share This Article